RU2018107056A - Полипептиды mrka, антитела к ним и пути их применения - Google Patents
Полипептиды mrka, антитела к ним и пути их применения Download PDFInfo
- Publication number
- RU2018107056A RU2018107056A RU2018107056A RU2018107056A RU2018107056A RU 2018107056 A RU2018107056 A RU 2018107056A RU 2018107056 A RU2018107056 A RU 2018107056A RU 2018107056 A RU2018107056 A RU 2018107056A RU 2018107056 A RU2018107056 A RU 2018107056A
- Authority
- RU
- Russia
- Prior art keywords
- antigen binding
- binding protein
- mrka
- antibody
- seq
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 3
- 229920001184 polypeptide Polymers 0.000 title claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 2
- 102000025171 antigen binding proteins Human genes 0.000 claims 88
- 108091000831 antigen binding proteins Proteins 0.000 claims 88
- 239000012634 fragment Substances 0.000 claims 37
- 238000000034 method Methods 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 230000002163 immunogen Effects 0.000 claims 18
- 241000588748 Klebsiella Species 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 229960005486 vaccine Drugs 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 230000028993 immune response Effects 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 241001534216 Klebsiella granulomatis Species 0.000 claims 3
- 241000588749 Klebsiella oxytoca Species 0.000 claims 3
- 241000588746 Raoultella planticola Species 0.000 claims 3
- 108091005948 blue fluorescent proteins Proteins 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- 101710154606 Hemagglutinin Proteins 0.000 claims 2
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 2
- 206010024652 Liver abscess Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 2
- 101710176177 Protein A56 Proteins 0.000 claims 2
- 208000007057 Pyogenic Liver Abscess Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000012575 bio-layer interferometry Methods 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 239000000185 hemagglutinin Substances 0.000 claims 2
- 230000008348 humoral response Effects 0.000 claims 2
- 230000002147 killing effect Effects 0.000 claims 2
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 2
- 230000000625 opsonophagocytic effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- 108010078777 Colistin Proteins 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 206010011409 Cross infection Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 208000032376 Lung infection Diseases 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000006816 Neonatal Sepsis Diseases 0.000 claims 1
- 206010029803 Nosocomial infection Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 206010062255 Soft tissue infection Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 102400000368 Surface protein Human genes 0.000 claims 1
- 206010048038 Wound infection Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 229960003346 colistin Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0266—Klebsiella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562208975P | 2015-08-24 | 2015-08-24 | |
| US62/208,975 | 2015-08-24 | ||
| US201562238828P | 2015-10-08 | 2015-10-08 | |
| US62/238,828 | 2015-10-08 | ||
| PCT/US2016/048221 WO2017035154A1 (en) | 2015-08-24 | 2016-08-23 | Mrka polypeptides, antibodies, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018107056A true RU2018107056A (ru) | 2019-09-26 |
Family
ID=58100831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018107056A RU2018107056A (ru) | 2015-08-24 | 2016-08-23 | Полипептиды mrka, антитела к ним и пути их применения |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20170073397A1 (enExample) |
| EP (1) | EP3341004A4 (enExample) |
| JP (1) | JP2018527924A (enExample) |
| KR (1) | KR20180042300A (enExample) |
| CN (1) | CN107921086A (enExample) |
| AU (1) | AU2016313653A1 (enExample) |
| BR (1) | BR112018003252A2 (enExample) |
| CA (1) | CA2995387A1 (enExample) |
| CL (1) | CL2018000357A1 (enExample) |
| CO (1) | CO2018001985A2 (enExample) |
| HK (1) | HK1252350A1 (enExample) |
| IL (1) | IL257434A (enExample) |
| MX (1) | MX2018001964A (enExample) |
| RU (1) | RU2018107056A (enExample) |
| TW (1) | TW201718626A (enExample) |
| WO (1) | WO2017035154A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201900027XA (en) * | 2016-08-05 | 2019-02-27 | Medimmune Llc | Anti-o2 antibodies and uses thereof |
| WO2018075375A1 (en) | 2016-10-19 | 2018-04-26 | Medimmune, Llc | Anti-o1 antibodies and uses thereof |
| JP2020525540A (ja) | 2017-06-23 | 2020-08-27 | ノソコミアル ヴァクスィーン コーポレイション | 免疫原性組成物 |
| CN115838430A (zh) * | 2022-07-08 | 2023-03-24 | 中国人民解放军陆军军医大学 | 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用 |
| CN116813725B (zh) * | 2023-07-06 | 2025-11-04 | 深圳康泰生物制品股份有限公司 | 肺炎克雷伯菌的FimA的抗原表位肽及其应用 |
| CN119798389A (zh) * | 2024-12-12 | 2025-04-11 | 中国人民解放军军事科学院军事医学研究院 | 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| WO2001010386A2 (en) * | 1999-08-11 | 2001-02-15 | Washington University | Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof |
| US7041465B1 (en) * | 1999-08-11 | 2006-05-09 | Washington University | Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof |
| WO2005034733A2 (en) * | 2003-10-08 | 2005-04-21 | North Shore-Long Island Jewish Research Institute | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| EA018030B1 (ru) * | 2006-06-06 | 2013-05-30 | Круселл Холланд Б.В. | Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения |
| GB0615662D0 (en) * | 2006-08-07 | 2006-09-13 | Affitech As | Antibody |
| EP2152731A2 (en) * | 2007-05-02 | 2010-02-17 | Intercell AG | Klebsiella antigens |
| GB0915403D0 (en) * | 2009-09-04 | 2009-10-07 | London School Hygiene & Tropical Medicine | Protein glycosylation |
| WO2011100700A2 (en) * | 2010-02-12 | 2011-08-18 | University Of Rochester | Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies |
| WO2012058334A1 (en) * | 2010-10-26 | 2012-05-03 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Morphology & protein specific reagents as diagnostics for neurodegenerative diseases |
| SMT202000542T1 (it) * | 2011-11-07 | 2020-11-10 | Medimmune Ltd | Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas |
-
2016
- 2016-08-23 MX MX2018001964A patent/MX2018001964A/es unknown
- 2016-08-23 HK HK18111635.8A patent/HK1252350A1/zh unknown
- 2016-08-23 TW TW105126946A patent/TW201718626A/zh unknown
- 2016-08-23 US US15/244,960 patent/US20170073397A1/en not_active Abandoned
- 2016-08-23 AU AU2016313653A patent/AU2016313653A1/en not_active Abandoned
- 2016-08-23 KR KR1020187007376A patent/KR20180042300A/ko not_active Withdrawn
- 2016-08-23 WO PCT/US2016/048221 patent/WO2017035154A1/en not_active Ceased
- 2016-08-23 BR BR112018003252A patent/BR112018003252A2/pt not_active Application Discontinuation
- 2016-08-23 RU RU2018107056A patent/RU2018107056A/ru not_active Application Discontinuation
- 2016-08-23 CA CA2995387A patent/CA2995387A1/en not_active Abandoned
- 2016-08-23 CN CN201680047771.3A patent/CN107921086A/zh active Pending
- 2016-08-23 EP EP16839995.4A patent/EP3341004A4/en not_active Withdrawn
- 2016-08-23 JP JP2018509904A patent/JP2018527924A/ja active Pending
-
2018
- 2018-02-08 CL CL2018000357A patent/CL2018000357A1/es unknown
- 2018-02-08 IL IL257434A patent/IL257434A/en unknown
- 2018-02-23 CO CONC2018/0001985A patent/CO2018001985A2/es unknown
- 2018-03-29 US US15/940,344 patent/US20190062411A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1252350A1 (zh) | 2019-05-24 |
| CL2018000357A1 (es) | 2018-07-20 |
| JP2018527924A (ja) | 2018-09-27 |
| TW201718626A (zh) | 2017-06-01 |
| US20170073397A1 (en) | 2017-03-16 |
| AU2016313653A1 (en) | 2018-04-12 |
| CO2018001985A2 (es) | 2018-11-22 |
| IL257434A (en) | 2018-04-30 |
| CN107921086A (zh) | 2018-04-17 |
| MX2018001964A (es) | 2018-06-19 |
| US20190062411A1 (en) | 2019-02-28 |
| EP3341004A1 (en) | 2018-07-04 |
| EP3341004A4 (en) | 2019-05-15 |
| WO2017035154A1 (en) | 2017-03-02 |
| BR112018003252A2 (pt) | 2018-09-25 |
| KR20180042300A (ko) | 2018-04-25 |
| CA2995387A1 (en) | 2017-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023075294A (ja) | 抗ｃｄ４７抗体及びその応用 | |
| RU2018107056A (ru) | Полипептиды mrka, антитела к ним и пути их применения | |
| JP2022177090A5 (enExample) | ||
| AU2012328921B2 (en) | Immunobinders directed against TNF | |
| RU2019132843A (ru) | Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение | |
| CN106496324B (zh) | 一种抗呼吸道合胞病毒的全人源抗体 | |
| CN114729033B (zh) | 抗α-溶血素的抗体及其应用 | |
| HRP20110599T1 (hr) | Antitijela protiv toksina clostridium difficile i njihove primjene | |
| JP2019516348A (ja) | 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途 | |
| JP2018527924A5 (enExample) | ||
| JP2020500005A5 (enExample) | ||
| US11365240B2 (en) | Anti-HSA antibodies | |
| US20250179195A1 (en) | Anti-flt3 antibodies and compositions | |
| HRP20192038T1 (hr) | Protutijela receptora anti-epidermalnog faktora rasta (egfr) | |
| ES2426093T3 (es) | Anticuerpo dirigido contra PcrV | |
| JP2017521054A5 (enExample) | ||
| BR112019022702A2 (pt) | gama de anticorpos anti-interferon e utilizações dos mesmos. | |
| CN113039208A (zh) | 一种抗pd-l1抗原结合蛋白及其应用 | |
| EP4353744A1 (en) | Antibody against respiratory syncytial virus and use thereof | |
| RU2013101769A (ru) | Высокоаффинные антитела человека к белку gb цитомегаловирусу (смv) человека | |
| US20240059764A1 (en) | ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF | |
| CN114685653B (zh) | 抗新冠病毒受体结合区域表位中和抗体及其应用 | |
| EP4608864A1 (en) | Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases | |
| KR20220148198A (ko) | 항-bcma 항체, 이의 약학 조성물 및 응용 | |
| CN119080917B (zh) | 特异性单克隆抗体及其在猴痘病毒检测、中和的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20190826 |